[Correspondence] Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”
- Clin. Mol. Hepatol., Volume 30(4); Oct 2024 | https://doi.org/10.3350/cmh.2024.0394